Toxicity of magnetic resonance imaging agents: small molecule and nanoparticle
- PMID: 23432006
- DOI: 10.2174/1568026611313040004
Toxicity of magnetic resonance imaging agents: small molecule and nanoparticle
Abstract
Magnetic resonance imaging (MRI) contrast agents have been used routinely for more than 20 years in order to increase sensitivity and specificity of lesion detection. MRI contrast agents (CAs) are usually categorized according to their magnetic behavior, biodistribution, and effect on the MR image. Typically, small molecular-weight gadolinium based CAs are examples of T1 agents, while magnetic nanoparticle (MNP) based CAs are examples of T2 agents. In addition to differences in magnetic relaxation behavior, small molecular-weight gadolinium based CAs and MNP based CAs show significantly different toxicity profiles. In the case of small molecular-weight gadolinium based CAs, many previous toxicological studies have reported favorable safety profiles of gadolinium based CAs. However, recently, a delayed serious adverse reaction known as nephrogenic systemic fibrosis (NSF) has been reported in patients, with a marked reduction in renal function after administration of certain types of gadolinium based CAs. For MNP based CAs, in addition to a wide spectrum of nanotoxicity common in nanomaterials, the emerging unexpected cytotoxicity of MNPs has become a new concern. Specifically, the combination of MNPs and strong static magnetic field (SMF) within MRI may give rise to potential adverse effects of MNPs in clinical application.
Similar articles
-
Pathomechanisms of nephrogenic systemic fibrosis: new insights.Clin Exp Dermatol. 2011 Oct;36(7):763-8. doi: 10.1111/j.1365-2230.2011.04136.x. Epub 2011 Jul 25. Clin Exp Dermatol. 2011. PMID: 21790732 Review.
-
NSF evaluation of gadolinium biodistribution in renally impaired rats: Using novel metabolic Gd2O3 nanoparticles coated with β-cyclodextrin (Gd2O3@PCD) in MR molecular imaging.Magn Reson Imaging. 2024 Apr;107:120-129. doi: 10.1016/j.mri.2024.01.003. Epub 2024 Jan 11. Magn Reson Imaging. 2024. PMID: 38215955
-
Gadolinium-based contrast agents and nephrogenic systemic fibrosis: why did it happen and what have we learned?J Magn Reson Imaging. 2009 Dec;30(6):1236-9. doi: 10.1002/jmri.21979. J Magn Reson Imaging. 2009. PMID: 19938035
-
Application of extracellular gadolinium-based MRI contrast agents and the risk of nephrogenic systemic fibrosis.Rofo. 2014 Jul;186(7):661-9. doi: 10.1055/s-0033-1356403. Epub 2014 Jan 29. Rofo. 2014. PMID: 24477507 Review.
-
Involvement of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: an update.Radiol Clin North Am. 2009 Sep;47(5):855-69, vii. doi: 10.1016/j.rcl.2009.06.006. Radiol Clin North Am. 2009. PMID: 19744600 Review.
Cited by
-
Grating-based phase-contrast imaging of tumor angiogenesis in lung metastases.PLoS One. 2015 Mar 26;10(3):e0121438. doi: 10.1371/journal.pone.0121438. eCollection 2015. PLoS One. 2015. PMID: 25811626 Free PMC article.
-
Mannan-Based Nanodiagnostic Agents for Targeting Sentinel Lymph Nodes and Tumors.Molecules. 2020 Dec 31;26(1):146. doi: 10.3390/molecules26010146. Molecules. 2020. PMID: 33396204 Free PMC article.
-
Pharmaceutical development and preclinical evaluation of a GMP-grade anti-inflammatory nanotherapy.Nanomedicine. 2015 Jul;11(5):1133-40. doi: 10.1016/j.nano.2015.02.020. Epub 2015 Mar 17. Nanomedicine. 2015. PMID: 25791805 Free PMC article.
-
Biological characterization of a novel hybrid copolymer carrier system based on glycogen.Drug Deliv Transl Res. 2018 Feb;8(1):73-82. doi: 10.1007/s13346-017-0436-x. Drug Deliv Transl Res. 2018. PMID: 29134553
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
